Breaking News, Collaborations & Alliances

Navigo Proteins Enters R&D Collaboration with SCK CEN for Targeted Radiotheranostics

This partnership will focus on the preclinical development of next-generation radiotheranostics, using the Auger-electron emitting radioisotope Terbium.

By: Rachel Klemovitch

Assistant Editor

Navigo Proteins GmbH announced a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, that will focus on the preclinical development of next-generation radiotheranostics, using the Auger-electron emitting radioisotope Terbium (161Tb). The partnership will leverage Navigo Proteins’ Affilin and HEAD platforms and knowledge of radiotheranostic development with SCK CEN’s expertise in radioisotopes. The two organizations aim to accelerate the development of rad...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics